Functional probiotic characterization and in vivo cholesterol-lowering activity of lactobacillus helveticus isolated from fermented cow milk

Journal of Microbiology and Biotechnology

Volumn 26, Issue 10, 2016, Pages 1675-1686

  Damodharan, Karthiyaini ^a   Palaniyandi, Sasikumar Arunachalam ^a   Yang, Seung Hwan ^b   Suh, Joo Won ^a  

^a Myong Ji University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Antihypertensive; Bioactive peptide; Cholesterol lowering; Lactobacillus helveticus; Probiotics

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CHOLESTEROL; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; HYPOCHOLESTEROLEMIC AGENT; ISOLEUCYL PROLYL PROLINE; KANAMYCIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; PROLINE DERIVATIVE; STREPTOMYCIN; TETRACYCLINE; TRIPEPTIDE; UNCLASSIFIED DRUG; VALYL PROLYL PROLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ATHEROGENESIS; BACTERIAL STRAIN; CACO 2 CELL LINE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FERMENTED PRODUCT; GENE; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS HELVETICUS; LDLR GENE; MALE; MILK; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SREBF2 GENE; ANIMAL; BODY WEIGHT; BOVINE; CACO-2 CELL LINE; CHEMISTRY; DRUG EFFECTS; EATING; FERMENTED MILK PRODUCT; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; METABOLISM; MICROBIOLOGY;

ANIMALS; BODY WEIGHT; CACO-2 CELLS; CATTLE; CHOLESTEROL; CULTURED MILK PRODUCTS; EATING; HUMANS; LACTOBACILLUS HELVETICUS; LIVER; MICE; MICE, INBRED ICR; PROBIOTICS;

EID: 84992448369     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1603.03005     Document Type: Article

References (54)

1. Ahire JJ, Bhat AA, Thakare JM, Pawar PB, Zope DG, Jain RM, Chaudhari BL. 2012. Cholesterol assimilation and biotransformation by Lactobacillus helveticus. Biotechnol. Lett. 34: 103-107.
2. Ahn T-G, Lee J-Y, Cheon S-Y, An H-J, Kook Y-B. 2013. Protective effect of Sam-Hwang-Sa-Sim-Tang against hepatic steatosis in mice fed a high-cholesterol diet. BMC Complement. Altern. Med. 13: 366.
3. Ammor MS, Florez AB, Mayo B. 2007. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. Food Microbiol. 24: 559-570.
4. Argyri AA, Zoumpopoulou G, Karatzas KA, Tsakalidou E, Nychas GJ, Panagou EZ, Tassou CC. 2013. Selection of potential probiotic lactic acid bacteria from fermented olives by in vitro tests. Food Microbiol. 33: 282-291.
5. Ashar MN, Prajapati JB. 1998. Bile tolerance, bile deconjugation and cholesterol reducing properties of dietary lactobacilli. Ind. J. Microbiol. 38: 145-148.
6. Ashar MN, Prajapati JB. 2000. Verification of hypocholesterolemic effect of fermented milk on human subjects with different cholesterol levels. Folia Microbiol. 45: 263-268.
7. Atassi F, Brassart D, Grob P, Graf F, Servin AL. 2006. In vitro antibacterial activity of Lactobacillus helveticus strain KS300 against diarrhoeagenic, uropathogenic and vaginosisassociated bacteria. J. Appl. Microbiol. 101: 647-654.
8. Begley M, Hill C, Gahan CG. 2006. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72: 1729-1738.
9. Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340.
10. Buck BL, Altermann E, Svingerud T, Klaenhammer TR. 2005. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Appl. Environ. Microbiol. 71: 8344-8351.
11. Cavallini DC, Suzuki JY, Abdalla DS, Vendramini RC, Pauly-Silveira ND, Roselino MN, et al. 2011. Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model. Lipids Health Dis. 10: 126.
12. Chauviere G, Coconnier M, Kerneis S, Fourniat J, Servin AL. 1992. Adhesion of human Lactobacillus acidophilus strain LB to human. J. Gen. Microbiol. 138: 1689-1696.
13. Chavez MN, Krone CL. 1976. Silicic acid thin-layer chromatography of conjugated and free bile acids. J. Lipid Res. 17: 545-547.
14. Chung Y-C, Jin H-M, Cui Y, Kim DS, Jung JM, Park J-I, et al. 2014. Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults. J. Funct. Foods 10: 465-474.
15. Cohen DE. 2008. Balancing cholesterol synthesis and absorption in the gastrointestinal tract. J. Clin. Lipidol. 2: S1-S3.
16. Damodharan K, Lee YS, Palaniyandi SA, Yang SH, Suh JW. 2015. Preliminary probiotic and technological characterization of Pediococcus pentosaceus strain KID7 and in vivo assessment of its cholesterol-lowering activity. Front. Microbiol. 6: 768.
17. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. 2014. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr Fgf15 axis in mice. Cell Rep. 7: 12-18.
18. Dimitrov Z, Gotova I, Chorbadjiyska E. 2014. Characterization of the adhesive factors of selected probiotics to Caco-2 epithelium cell line. Biotechnol. Biotechnol. Equip. 28: 1079-1083.
19. EFSA. 2012. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA J. 10: 2740.
20. EFSA. 2007. The introduction of a qualified presumption of safety (QPS) approach for assessment of selected microorganisms referred to EFSA. EFSA J. 587: 1-16.
21. FAO/WHO. 2001. Expert consultation on health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO, Córdoba, Argentina.
22. Fortina MG, Nicastro G, Carminati D, Neviani E, Manachini PL. 1998. Lactobacillus helveticus heterogeneity in natural cheese starters: the diversity in phenotypic characteristics. J. Appl. Microbiol. 84: 72-80.
23. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
24. Gonzalez-Gonzalez C, Gibson T, Jauregi P. 2013. Novel probiotic-fermented milk with angiotensin I-converting enzyme inhibitory peptides produced by Bifidobacterium bifidum MF 20/5. Int. J. Food Microbiol. 167: 131-137.
25. Gyarfas I, Keltai M, Salim Y. 2006. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study. Orv. Hetil. 147: 675-686.
26. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11: 506-514.
27. Hu Y, Stromeck A, Loponen J, Lopes-Lutz D, Schieber A, Ganzle MG. 2011. LC-MS/MS quantification of bioactive angiotensin I-converting enzyme inhibitory peptides in rye malt sourdoughs. J. Agric. Food Chem. 59: 11983-11989.
28. Lye HS, Rahmat-Ali GR, Liong M-T. 2010. Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int. Diary J. 20: 169-175.
29. Jebava I, Chuat V, Lortal S, Valence F. 2014. Peptidoglycan hydrolases as species-specific markers to differentiate Lactobacillus helveticus from Lactobacillus gallinarum and other closely related homofermentative lactobacilli. Curr. Microbiol. 68: 551-557.
30. Jiang J, Hang X, Zhang M, Liu X, Li D, Yang H. 2010. Diversity of bile salt hydrolase activities in different lactobacilli toward human bile salts. Ann. Microbiol. 60: 81-88.
31. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. 2008. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Natl. Acad. Sci. USA 105: 13580-13585.
32. Karska-Wysocki B, Bazo M, Smoragiewicz W. 2010. Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol. Res. 165: 674-686.
33. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. 2004. Worldwide prevalence of hypertension: a systematic review. J. Hypertension 22: 11-19.
34. Korhonen H, Pihlanto A. 2006. Bioactive peptides: production and functionality. Int. Dairy J. 16: 945-960.
35. Seppo L, Jauhiainen T, Poussa T, Korpela R. 2003. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. Am. J. Clin. Nutr. 77: 326-330.
36. Lievin-Le Moal V, Servin AL. 2014. Anti-infective activities of Lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin. Microbiol. Rev. 27: 167-199.
37. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25: 402-408.
38. Maeno M, Yamamoto N, Takano T. 1996. Identification of an antihypertensive peptide from casein hydrolysate produced by a proteinase from Lactobacillus helveticus CP790. J. Dairy Sci. 79: 1316-1321.
39. Nakamura Y, Yamamoto N, Sakai K, Takano T. 1995. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J. Dairy Sci. 78: 1253-1257.
40. Saito M, Seki M, Iida K-I, Nakayama H, Yoshida S-I. 2007. A novel agar medium to detect hydrogen peroxideproducing bacteria based on the Prussian blue-forming reaction. Microbiol. Immunol. 51: 889-892.
41. Seppo L, Jauhiainen T, Poussa T, Korpela R. 2003. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am. J. Clin. Nutr. 77: 326-330.
42. Yeon SW, You YS, Kwon HS, Yang EH, Ryu JS, Kang BH, Kang J-H. 2010. Fermented milk of Lactobacillus helveticus IDCC3801 reduces beta-amyloid and attenuates memory deficit. J. Funct. Foods 2: 143-152.
43. Strahinic I, Lukic J, Terzic-Vidojevic A, Lozo J, Kojic M, Topisirovic L. 2013. Use of Lactobacillus helveticus BGRA43 for manufacturing fermented milk products. Food Technol. Biotechnol. 51: 257-265.
44. Takemura N, Okubo T, Sonoyama K. 2010. Lactobacillus plantarum strain no. 14 reduces adipocyte size in mice fed high-fat diet. Exp. Biol. Med. 235: 849-856.
45. Tanaka H, Doesburg K, Iwasaki T, Mierau I. 1999. Screening of lactic acid bacteria for bile salt hydrolase activity. J. Dairy Sci. 82: 2530-2535.
46. Tanida M, Shen J, Maeda K, Horii Y, Yamano T, Fukushima Y, Nagai K. 2008. High-fat diet-induced obesity is attenuated by probiotic strain Lactobacillus paracasei ST11 (NCC2461) in rats. Obes. Res. Clin. Pract. 2: I-II.
47. Taverniti V, Guglielmetti S. 2012. Health-promoting properties of Lactobacillus helveticus. Front. Microbiol. 3: 392.
48. Trautwein EA, Rieckhoff D, Erbersdobler HF. 1998. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. J. Nutr. 128: 1937-1943.
49. Tuo Y, Yu H, Ai L, Wu Z, Guo B, Chen W. 2013. Aggregation and adhesion properties of 22 Lactobacillus strains. J. Dairy Sci. 96: 4252-4257.
50. Wang H, Chen G, Ren D, Yang S-T. 2014. Hypolipidemic activity of Okra is mediated through inhibition of lipogenesis and upregulation of cholesterol degradation. Phytother. Res. 28: 268-273.
51. Wiegand I, Hilpert K, Hancock RE. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3: 163-175.
52. Yamamoto N, Akino A, Takano T. 1994. Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus CP790. J. Dairy Sci. 77: 917-922.
53. Yamamoto N, Akino A, Takano T. 2014. Antihypertensive effects of different kinds of fermented milk in spontaneously hypertensive rats. Biosci. Biotechnol. Biochem. 58: 776-778.
54. Yamamoto N, Maeno M, Takano T. 1999. Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. J. Dairy Sci. 82: 1388-1393.